Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Herstal

1 407 clinical trials in Herstal, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Herstal at a glance
1 407
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 407 trials in Herstal

Open in trial search

A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Phase III Randomized Study of Balcinrenone and Dapagliflozin Versus Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease Stage 3b‑4

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB

Immunisation+3

Recruiting

SARS‑CoV‑2 spike protein vaccine and drug combination study in adults 60 years and older with COVID‑19 and influenza

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:TAK-019
  • Sponsor:Sanofi Pasteur Inc.

Obesity+1

Recruiting

Phase 3 Extension Trial Evaluating Long‑Term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Narcolepsy

Recruiting

Phase 3 Study of Pitolisant for Excessive Daytime Sleepiness in Narcolepsy Patients

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pitolisant
  • Sponsor:Harmony Biosciences Management Inc.

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Study of lunsekimig versus placebo in adults with inadequately controlled eosinophilic COPD

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ZL-1310
  • Sponsor:Zai Lab (US) LLC

Vitiligo

Recruiting

Efficacy and Safety of LY4005130 Compared with Placebo in Adults with Non‑Segmental Vitiligo

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:LY4005130
  • Sponsor:Eli Lilly & Co.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Herstal

What the registry says about research in the country

01 Immune System Diseases

Clinical research in Herstal is focused on immune system diseases, with all currently listed studies centered on atopic dermatitis. These trials are examining whether a new treatment approach can better control symptoms and improve everyday skin health for people living with moderate-to-severe disease.

  • Testing a new therapy for better control of atopic dermatitis
  • Comparing treatment effectiveness against placebo
  • Assessing improvements in skin signs and symptom severity

The research program in this Belgian city is aimed at understanding how well treatment options work for patients who need stronger support than standard care alone.

02 Atopic Dermatitis

The main disease under study is atopic dermatitis, a chronic inflammatory skin condition that can cause itching, redness, and discomfort. Current trials are looking at whether a targeted therapy can offer meaningful relief, either on its own or alongside common skin treatments.

  • Evaluating a new option for moderate-to-severe atopic dermatitis
  • Studying treatment used with topical corticosteroids and topical calcineurin inhibitors
  • Measuring changes in disease control and visible skin improvement
  • Supportive research for patients seeking better symptom management

These studies are designed to help clarify whether newer approaches can improve outcomes for people whose skin disease remains difficult to manage.

03 Topical Combination Treatment Research

Another important area of research is the use of topical corticosteroids and topical calcineurin inhibitors alongside investigational therapy. This work is focused on evaluating how combination treatment may improve relief and disease control compared with standard topical care alone.

  • Studying combination care for moderate-to-severe atopic dermatitis
  • Assessing whether added therapy improves overall response
  • Looking at clinical signs and severity over time

The trials in Belgium reflect a practical clinical question: whether pairing new and established treatments can lead to better outcomes for patients.

04 Therapeutic Innovation in Skin Inflammation

The local trial landscape is small but concentrated, with all active studies exploring a single inflammatory skin condition. This makes Herstal a focused site for research on newer therapies aimed at reducing the burden of persistent eczema symptoms.

  • Exploring a new treatment for inflammatory skin disease
  • Comparing benefit against standard control approaches
  • Helping define better options for routine patient care

Overall, the studies are centered on improving treatment effectiveness and expanding options for people living with difficult-to-treat skin inflammation.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.